For the latest news and information on the coronavirus pandemic, visit the WHO website.
Will we have onevaccine before the general election on November 3? President Donald Trump and vaccine developer Pfizer seem to believe it, but the World Health Organization does not agree. WHO spokeswoman Margaret Harris told a UN review in Geneva: “We really do not expect to receive a comprehensive vaccination until the middle of next year.” So why has the Centers for Disease Control and Prevention announced all 50 states and several major US cities to be ready to distribute a vaccine by the end of October? The answer, some say, is about politics.
Political pressure to approve a vaccine before election day has become so great, it has got nine of the most prominent biopharmaceutical companies currently working with a COVID-19 vaccine to sign a letter promising to fully veterinate their experimental drugs before they asks for government approval. And while it may seem obvious, Russia has already approved a vaccine way before it has been thoroughly tested, and China has begun administering a vaccine to military and medical personnel despite incomplete testing.
There are currently seven vaccine candidates being tested in the United States, three of which are approaching the final stages required for approval by the Food and Drug Administration. Given that SARS-CoV-2 – the virus that causes COVID-19 – was discovered just eight months ago, progress is actually being made in a faster cut than ever before in the history of infectious disease, despite Trump’s claim that vaccine development is deliberately stifled (vaccines take on average about 10.7 years to develop).
Here we map the current landscape for a coronavirus vaccine that is being developed. This article is frequently updated and is intended to be a general overview, not a source of medical advice. If you are looking for more information about coronavirus testing, you will find a test site near you.
Important news about COVID-19 vaccine
A major trial of the coronavirus vaccine has put on hold and the start of US tests has been delayed while researchers are investigating whether a case of back inflammation in a volunteer was related to the vaccine developed by Oxford University and AstraZeneca.
Pfizer and BioNTech believe they may have a coronavirus vaccine ready for approval in October or November, according to BioNTech founder and CEO Ugur Sahin.
“It is unlikely that we will get a definitive answer” in the election on November 3, according to Dr. Anthony Fauci, the United States’ highest official in infectious diseases.
Most people in the United States will not be able to get a vaccine until 2021, even if one or more are approved before the end of 2020, according to an early draft of a possible vaccination plan released in August by the National Academy of Sciences.
Mexico could get its own coronavirus vaccine this spring, according to a researcher responsible for coordinating the country’s efforts, who said the drug will undergo a complete three-phase screening process before being approved.
New York State Coronavirus positivity has dropped to 1% for 30 straight days after hitting one of the most serious outbreaks in the entire country.
A nationwide shortage of dry ice can slow down coronavirus vaccine distribution, according to Boston’s NPR news station, as some vaccine candidates require temperatures below zero during storage.
COVID vaccine development is accelerating
Several acceleration efforts are currently underway, such as the White House’s operation Warp Speed, which is intended to cut through the regulatory agency to accelerate vaccine development and be ready to distribute vaccines as soon as they receive FDA approval. To date, the US government has promised more than $ 10 billion to several vaccine manufacturers to secure a total of 800 million vaccine doses.
Vaccines usually take about 10 to 15 years to develop and approve through four phases that include human trials. But with Operation Warp Speed, approved vaccine projects can submit data to the FDA bit by bit instead of submitting all sections of the application after all four phases are completed.
At the same time, the program also financially supports efforts to start production doses while clinical trials are still ongoing. This means that if and when these vaccines are approved, there will already be a stock of doses ready to be distributed nationally. “I hope that by the time we get well into the second half of 2021, companies will have delivered the hundreds of millions of doses they have promised,” says Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases. , Forbes reported in August.
Promising coronavirus vaccines from the UK, USA, China
Here’s a quick look at some of the fronts in the race to find a COVID-19 vaccine, including where the vaccines are being developed, where they are being tested and when researchers believe they may be ready for widespread distribution, if known.
Oxford University / AstraZeneca (UK): AstraZeneca has suspended testing of its vaccine, as it had begun on 100,000 human volunteers in at least three countries, and is preparing to begin in the United States. Leading researcher Dr Sarah Gilbert had originally said that they were aiming for a release in the autumn of 2020, which can now be delayed. However, Britain’s health minister Matt Hancock has said such a break is not “necessarily” a setback.
Modern (US): An obvious battle with state regulators delayed large-scale human testing, but Moderna’s CEO has told Barrons that he still expects the company to know from Thanksgiving if the vaccine is safe and effective and should be able to distribute it in early 2021 if it is.
Pfizer (USA): Although its four COVID-19 vaccine candidates are still in human early studies, two of them have been rapidly detected by the FDA. Pfizer’s business director told the US Congress that the company may be ready to apply for FDA approval in October.
SinoVac (China): It is currently testing its vaccine on about 10,000 human volunteers in China and about 9,000 in Brazil and will soon begin testing on about 1,900 test subjects in Indonesia. The CEO of BioPharma, SinoVac’s Indonesian partner, has said he expects the vaccine to be ready in early 2021.
SinoPharm (China): Currently, about 15,000 volunteers in the Middle East are testing in a trial that the state-owned company expects to last for three to six months. Early results suggest that the drug is safe and at least somewhat effective. SinoPharm recently built a second plant to manufacture the vaccine and doubled its capacity to approximately 200 million doses per year.
CanSino Biologics (China): CanSino’s vaccine has already been approved for the Chinese military at the start of major human trials this summer. The vaccine is based on a modified cold virus, which some experts warn against making it less effective than other vaccines.
Will there just be one vaccine for everyone?
We probably won’t know until next year, but Fauci has suggested that it may require several different vaccines manufactured and distributed by different laboratories to end the pandemic, in an article published May 11 in the journal Science.
What happens if we never find a coronavirus vaccine?
Coronavirus is a large class of viruses and so far there are no vaccines against any of them. Although there are promising early results, there is no guarantee of a vaccine until 2021. Statistically, only about 6% of vaccine candidates will ever make it to market, according to a Reuters special report.
Early evidence suggests that the coronavirus does not appear to mutate as rapidly or frequently as the flu, and it is believed that the virus has not yet mutated significantly enough to interfere with vaccine development – although our knowledge may change.
The further we go without a vaccine, the more likely the focus will shift to treatments, such as, which reportedly showed promising results, and , a steroid that doctors say increases the survival rate among the most serious cases. With effective therapeutic treatments, many viruses that were previously lethal are no longer death sentences. Patients with HIV, for example, can now expect to have the same life expectancy as non-HIV-positive individuals, thanks to tremendous advances in treatment.
Eventually, the global population can reach the 60-70% required forto protect those who are not immune, which is ultimately the goal of a vaccine.